α2-巨球蛋白及其糖基化在恶性肿瘤中的研究进展

doi:10.3969/j.issn.1673-8640.2017.010.020

摘要/Abstract

摘要：

α₂-巨球蛋白（α₂-MG）是血浆中相对分子质量最大的蛋白质,由肝细胞与单核-巨噬细胞系统合成,是由4个相同的亚基组成的同源四聚体结构。α₂-MG是血浆中一种广谱的蛋白酶抑制剂,参与多种疾病的病理生理过程。文章对α₂-MG的结构和功能及其糖基化进行了简要阐述,并对α₂-MG与肝癌、卵巢癌、前列腺癌、乳腺癌、非小细胞肺癌和其他常见恶性肿瘤的关系以及α₂-MG糖基化与恶性肿瘤关系的研究进展进行了综述。

关键词: α2-巨球蛋白, 血清标志物, 糖蛋白, 蛋白酶抑制剂, 糖基化, 肿瘤

Abstract:

Alpha-2-macroglobulin（α₂-MG） is the largest protein in plasma,which is synthesized by liver cells and mononuclear macrophage system. Human α₂-MG is a homotetramer comprised of 4 same subunits. As a broad spectrum protease inhibitor in plasma,α₂-MG is involved in the pathophysiology of many diseases. In this review,the structure and function of α₂-MG and its glycosylation are briefly expounded. The research progress on the relationship of α₂-MG with liver cancer and other common malignant tumors are reviewed,as well as the research progress on the relationship between α₂-MG glycosylation and carcinogensis.

Key words: Alpha-2-macroglobulin, Serum marker, Glycoprotein, Protease inhibitor, Glycosylation, Tumor

中图分类号:

R446.1

詹先林, 闫伟（综述）, 高春芳（审校）. α₂-巨球蛋白及其糖基化在恶性肿瘤中的研究进展[J]. 检验医学, 2017, 32(10): 922-927.

ZHAN Xianlin, YAN Wei, GAO Chunfang. Research progress on alpha-2-macroglobulin and its glycosylation in tumor[J]. Laboratory Medicine, 2017, 32(10): 922-927.

参考文献 40

[1]	BAKER A H,EDWARDS D R,MURPHY G.Metalloproteinase inhibitors:biological actions and therapeutic opportunities[J]. J Cell Sci,2002,115(Pt 19):3719-3727.
[2]	REHMAN A A,AHSAN H,KHAN F H.Identification of a new alpha-2-macroglobulin:multi-spectroscopic and isothermal titration calorimetry study[J]. Int J Biol Macromol,2016,83:366-375.
[3]	皇甫超济,吕茂民,马玉媛,等. α2-巨球蛋白活性检测方法的建立与优化[J]. 军事医学,2015,60(3):193-195.
[4]	PAIVA M M,SOEIRO M N,BARBOSA H S,et al.Glycosylation patterns of human alpha2-macroglobulin:analysis of lectin binding by electron microscopy[J]. Micron,2010,41(6):666-673.
[5]	LIN Z,LO A,SIMEONE D M,et al.An N-glycosylation analysis of human alpha-2-macroglobulin using an integrated approach[J]. J Proteomics Bioinform,2012,5:127-134.
[6]	PANZIRONI C,SILVESTRINI B,MO M Y,et al.An increase in the carbohydrate moiety of alpha 2-macroglobulin is associated with systemic lupus erythematosus(SLE)[J]. Biochem Mol Biol Int,1997,43(6):1305-1322.
[7]	皇甫超济,吕茂民,马玉媛,等. α2-巨球蛋白的特性与功能[J]. 中国输血杂志,2016,29(2):217-222.
[8]	BORTH W.Alpha 2-macroglobulin,a multifunctional binding protein with targeting characteristics[J]. FASEB J,1992,6(15):3345-3353.
[9]	CHEN X,KONG X,ZHANG Z,et al.Alpha-2-macroglobulin as a radioprotective agent:a review[J]. Chin J Cancer Res,2014,26(5):611-621.
[10]	LEGRES L G,POCHON F,BARRAY M,et al.Human alpha 2-macroglobulin as a cytokine-binding plasma protein. A study with rh-interleukin-1 beta and rh-interleukin-6[J]. Ann N Y Acad Sci,1994,737:439-443.
[11]	SATO M,YAO V J,ARAP W,et al.GRP78 signaling hub a receptor for targeted tumor therapy[J]. Adv Genet,2010,69:97-114.
[12]	CARVALHO S,TROOST E G,BONS J,et al.Prognostic value of blood-biomarkers related to hypoxia,inflammation,immune response and tumour load in non-small cell lung cancer-a survival model with external validation[J]. Radiother Oncol,2016,119(3):487-494.
[13]	KIM J H,KIM Y W,KIM I W,et al.Identification of candidate biomarkers using the ExperionTM automated electrophoresis system in serum samples from ovarian cancer patients[J]. Int J Oncol,2013,42(4):1257-1262.
[14]	MAZOUNI C,BAGGERLY K,HAWKE D,et al.Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure[J]. Proteomics,2010,10(19):3525-3532.
[15]	SUNDERIC M,SEDIVA A,ROBAJAC D,et al.Lectin-based protein microarray analysis of differences in serum alpha-2-macroglobulin glycosylation between patients with colorectal cancer and persons without cancer[J]. Biotechnol Appl Biochem,2016,63(4):457-464.
[16]	LIN Z,YIN H,LO A,et al.Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS[J]. Electrophoresis,2014,35(15):2108-2115.
[17]	KUROKAWA Y,MATOBA R,TAKEMASA I,et al.Molecular features of non-B,non-C hepatocellular carcinoma:a PCR-array gene expression profiling study[J]. J Hepatol,2003,39(6):1004-1012.
[18]	KAR P,GANDHI B M,IRSHAD M,et al.Alpha-2 macroglobulin: an additional marker for diagnosis of hepatocellular carcinoma[J]. J Assoc Physicians India,1987,35(4):288-289.
[19]	李丽. 岩藻糖基化修饰蛋白在原发性肝细胞癌中的研究进展[J]. 检验医学,2012,27(4):324-328.
[20]	POON T C,CHAN A T,ZEE B,et al.Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma[J]. Oncology,2001,61(4):275-283.
[21]	SUKATA T,UWAGAWA S,OZAKI K,et al.Alpha(2)-macroglobulin: a novel cytochemical marker characterizing preneoplastic and neoplastic rat liver lesions negative for hitherto established cytochemical markers[J]. Am J Pathol,2004,165(5):1479-1488.
[22]	NOMURA F,OHNISHI K,TANABE Y.Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients[J]. Cancer,1989,64(8):1700-1707.
[23]	ZHAO S,LI H,WANG Q,et al.The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M[J]. BMC Cancer,2015,15:389.
[24]	JEMAL A,SIEGEL R,WARD E,et al.Cancer statistics,2008[J]. CA Cancer J Clin,2008,58(2):71-96.
[25]	VISINTIN I,FENG Z,LONGTON G,et al.Diagnostic markers for early detection of ovarian cancer[J]. Clin Cancer Res,2008,14(4):1065-1072.
[26]	SHIELD-ARTIN K L,BAILEY M J,OLIVA K,et al. Identification of ovarian cancer-associated proteins in symptomatic women:a novel method for semi-quantitative plasma proteomics[J]. Proteomics Clin Appl,2012,6(3-4):170-181.
[27]	KANOH Y,OHTANI N,MASHIKO T,et al.Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer[J]. Anticancer Res,2001,21(1B):551-556.
[28]	PARTIN A W,YOO J,CARTER H B,et al.The use of prostate specific antigen,clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer[J]. J Urol,1993,150(1):110-114.
[29]	KANOH Y,OHTANI H,KOSHIBA K.Studies on alpha 2 macroglobulin deficiency in association with cancer metastasis[J]. Nihon Rinsho Meneki Gakkai Kaishi,1997,20(1):30-43.
[30]	LIEDTKE C,MAZOUNI C,HESS K R,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol,2008,26(8):1275-1281.
[31]	CHO W C,CHENG C H.Oncoproteomics: current trends and future perspectives[J]. Expert Rev Proteomics,2007,4(3):401-410.
[32]	PUSZTAI L,GREGORY B W,BAGGERLY K A,et al.Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma[J]. Cancer,2004,100(9):1814-1822.
[33]	CARVALHO S,TROOST E G,BONS J,et al.Prognostic value of blood-biomarkers related to hypoxia,inflammation,immune response and tumour load in non-small cell lung cancer-a survival model with external validation[J]. Radiother Oncol,2016,119(3):487-494.
[34]	SIMONE C N 2nd,BURRI S H,HEINZERLING J H. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies[J]. Transl Lung Cancer Res,2015,4(5):545-552.
[35]	BRAOUDAKI M,LAMBROU G I,VOUGAS K,et al.Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner[J]. J Hematol Oncol,2013,6:52.
[36]	CAVALCANTE MDE S,TORRES-ROMERO J C,LOBO M D,et al. A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia[J]. Biomark Res,2016,4:1.
[37]	LUO Y,DENG Z,CHEN J.Pivotal regulatory network and genes in osteosarcoma[J]. Arch Med Sci,2013,9(3):569-575.
[38]	NIU F,ZHAO S,XU C Y,et al.Identification and functional analysis of differentially expressed genes related to metastatic osteosarcoma[J]. Asian Pac J Cancer Prev,2015,15(24):10797-10801.
[39]	CLERC F,REIDING K R,JANSEN B C,et al.Human plasma protein N-glycosylation[J]. Glycoconj J,2016,33(3):309-343.
[40]	DUBE D H,BERTOZZI C R.Glycans in cancer and inflammation-potential for therapeutics and diagnostics[J]. Nat Rev Drug Discov,2005,4(6):477-488.

α₂-巨球蛋白及其糖基化在恶性肿瘤中的研究进展

Research progress on alpha-2-macroglobulin and its glycosylation in tumor

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

编辑推荐

Metrics

[1]	周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811.
[2]	王杨淑怡, 叶威, 林志豪, 黄约诺, 方涛, 董晓亭. 肺腺癌焦亡相关特征模型的构建和验证[J]. 检验医学, 2023, 38(9): 833-841.
[3]	彭伟, 李运改, 许静, 刘华, 杨翠霞, 沈云岳. 血清炎症因子联合PSA、f-PSA可辅助诊断前列腺癌[J]. 检验医学, 2023, 38(9): 849-854.
[4]	卫明珠, 潘继文, 罗锐, 陈俊辉. 凝血4项和肿瘤标志物对乙型肝炎相关肝癌的辅助诊断价值[J]. 检验医学, 2023, 38(9): 901-904.
[5]	丁肖媛, 戴劲盛, 焦荣红, 马素丽, 朱海峰, 吴梦雅, 车艳然, 张蕾. 肥胖/超重对哮喘发作期患儿Th1/Th2和Th17/Treg细胞因子的影响[J]. 检验医学, 2023, 38(8): 748-752.
[6]	汪海平, 李贺. BISAP评分联合血清sRAGE评估急性高脂血症性胰腺炎严重程度和短期预后的价值[J]. 检验医学, 2023, 38(7): 653-658.
[7]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[8]	赵婧, 王佩, 卢丹丹, 齐丹丹, 李轩. 出血性脑卒中患者血清miR-4443、TRAF4相对表达量变化的临床意义[J]. 检验医学, 2023, 38(5): 413-418.
[9]	高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306.
[10]	刘瑞丽, 李兰军, 贾旻蕾, 王一惠, 郝维纳. 胃癌组织miR-7-5p、NOVA2表达与患者临床预后的相关性[J]. 检验医学, 2023, 38(4): 325-329.
[11]	宋世伟, 李景武, 林韬, 刘泽宇, 王志强, 孙卫东. GPNMB与非小细胞肺癌患者肿瘤免疫浸润和预后的相关性[J]. 检验医学, 2023, 38(4): 347-351.
[12]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[13]	张智香, 田恒峰, 衡二虎. 先天性糖基化障碍Ⅰq型患儿基因检测结果分析和文献回顾[J]. 检验医学, 2023, 38(2): 137-142.
[14]	吴炯, 胡嘉华, 施美芳, 刘涛, 戴洁, 卢忻怡, 邹政. 前列腺癌生物标志物研究进展[J]. 检验医学, 2023, 38(2): 190-195.
[15]	顾玉, 梁晓艳, 马胜辉, 佟娜, 程明艳, 阎泽君. 血浆生物标志物在慢性肾脏病伴血栓栓塞患者中的表达及其近期预后评估价值[J]. 检验医学, 2023, 38(12): 1177-1182.